AstraZeneca has made a bold move to expand its respiratory franchise by buying up drugs and pipeline candidates from Spanish pharma company Almirall. AstraZeneca will pay the Barcelona ...

AstraZeneca is to pay up to $225 million to develop and market a respiratory drug which could help restore its position in the therapy area. The company has a heritage in respiratory drugs ...

For over five decades, AstraZeneca has been at the forefront of serving respiratory patients through substantial investments ...

Asthma is advancing relentlessly across the African continent. Today, 70% of African asthma and COPD sufferers are undiagnosed and the WHO forecasts a 20% increase in respiratory related deaths in the ...